ALK inhibitors and advanced non-small cell lung cancer (Review)

Treatment of unselected patients with advanced non-small cell lung cancer (NSCLC) receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. Histology and molecular analyses are the cornerstone in the initial diagnosis of NSCLC and are key determinants to address...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of oncology 2014-08, Vol.45 (2), p.499-508
Hauptverfasser:	ROSSI, ANTONIO, MAIONE, PAOLO, SACCO, PAOLA CLAUDIA, SGAMBATO, ASSUNTA, CASALUCE, FRANCESCA, FERRARA, MARIANNA LUCIANA, PALAZZOLO, GIOVANNI, CIARDIELLO, FORTUNATO, GRIDELLI, CESARE
Format:	Artikel
Sprache:	eng
Schlagworte:	ALK Analysis Anaplastic lymphoma kinase (ALK) inhibitor Antineoplastic Agents - therapeutic use Brain cancer brain metastases Cancer research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Care and treatment Chemotherapy crizotinib Development and progression Genetic aspects Growth factors Health aspects HSP90 inhibitors Humans Kinases LDK378 Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics mechanisms of resistance Metastasis Monoclonal antibodies Mutation Non-small cell lung cancer NSCLC pemetrexed Precision medicine Protein Kinase Inhibitors - therapeutic use Proteins Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Response rates ROS1 Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!